Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

[cafead]

via Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in various forms of cancer.

article source